Blackpoint Biotech plc is incorporated under the laws of England and Wales under the Companies Act 2006 and the company number 14326849. The Company’s shares are traded on the Aquis Exchange
The Company's principal activity is that of a holding company. The Group's principal activity is the development and provision of cannabinoid based unlicensed medicines to patients under prescription via metered dose devices
The Company is headquartered in the UK with its registered office at 48-49 Chancery Lane, c/o Keystone Law, London WC2A 1JF
The total issued share capital of the Company is 12,187,179 ordinary shares with a nominal value of £0.005 each. Warrants have been issued over 40,000 ordinary shares, equivalent to 0.3% of issued share capital
15.12% of issued shares are in public hands
10,036,208 issued shares are subject to a Lock-In until 20 July 2024. From 20 July 2024 until 20 July 2025 8,028,967 shares are subject to Lock-In and from 20 July 2025 until 20 July 2026 6,423,175 shares are subject to Lock-In. Any sales from these 10,036,208 shares are subject to an Orderly Market Agreement until 20 July 2026
No securities are held in treasury. There are no restrictions on the transfer of securities
Legal Entity Identifier: 9845006C113DC43E7650, ISIN: GB00BNNSQQ91, SEDOL: BNNSQQ9, Stock Exchange ticker: BKPT
Mike Balfour OBE FCA
Mike Balfour OBE is an experienced Chairman, investor and a past winner of the EY Entrepreneur of the Year award. Mike was the founder and CEO of Fitness First which he transformed into one of the world’s largest chain of fitness clubs. Fitness First was floated on AIM in 1996 at £14m and went on to be sold to private equity in 2005 for £835m. Mike is actively involved in a number of health and healthcare related businesses.
Alex Wakeford FCA
Chief Financial Officer
Alex Wakeford trained as a Chartered Accountant with PwC and has over 18 years of experience in financial and operational management and corporate finance. Alex’s previous roles include being the Finance Director at online travel agent Secret Escapes where he built the finance function to enable the company’s growth from a start-up to a £650m t/o business with c.1,000 staff over 16 countries. Alex has undertaken multiple debt, equity and M&A transactions. Before Secret Escapes Alex spent 10 years at PwC, Deloitte and Barclays Capital.
Dr. Michael Mayne
Chief Product Officer
Dr Michael Mayne has over 20 years of experience as a senior executive in Canadian federal and provincial governments. Michael received his training in pharmacology and medicine at the University of Toronto (PhD), University of Manitoba (Post-doctoral) and National Institutes of Health in Bethesda (Fellowship). Michael has pioneered the Company’s use of MDD technology for cannabis products.
Founder and CEO
David Martinez is a Gibraltarian entrepreneur with a degree in Business with Accounting & Finance. He previously founded an award winning hemp-based CBD company and grew it to become a market leader in Eastern Europe. David has amassed a wealth of knowledge across the medicinal cannabis space, especially in regulatory affairs. David played a key role in acquiring the first cannabis licence for CannaSVG Ltd and the first psychedelics licence for Psyched Therapeutics Ltd.
The Company's AQSE Corporate Advisor is First Sentinel Corporate Finance Limited
The Company's auditor is MAH, Chartered Accountants
The Company's registrar is Neville Registrars Limited
The Company's company secretary is MSP Corporate Services Limited
The Company's English Law legal advisers are Keystone Law Limited and Gibraltarian Law legal advisers are Hassans International Law Firm
The Directors are committed to maintaining high standards of corporate governance, and, so far as is practicable given the Company’s size and nature, to comply with the QCA Code.
The Board has three formally established committees – Remuneration, Audit and Risk, and AQSE Rules Compliance.
The Board holds at least four board meetings a year but also holds more timely board meetings as and when issues arise which require its attention. The Board is responsible for the management of the business of the Company, setting the strategic direction of the Company.
The Company has established financial procedures and has adopted an anti-bribery and corruption policy.
Audit and Risk Committee
The Board has established an Audit and Risk Committee with formally delegated duties and responsibilities. The Audit and Risk Committee comprises Michael Balfour, as Chairman, and David Martinez. It is intended that any future independent non-executive directors appointed to the Board shall be appointed as members of this committee either in addition to David Martinez or as his replacement. The Audit and Risk Committee will meet at least three times per year and will be responsible for ensuring the financial performance of the Company is properly reported on and monitored, including reviews of the annual and interim accounts, results announcements, internal control systems and procedures, and accounting policies, as well as keeping under review the categorisation, monitoring and overall effectiveness of the Company's risk assessment and internal control processes.
The Remuneration Committee comprises Michael Balfour, as Chairman, and David Martinez, and is responsible for the review and recommendation of the scale and structure of remuneration for the Company's senior managers, including any bonus arrangements or the award of share options with due regard to the interests of Shareholders and the Group's performance. The Remuneration Committee will meet at least annually.
AQSE Rules Compliance Committee
The AQSE Rules Compliance Committee will comprise Michael Balfour, as Chairman, and Alex Wakeford, and will meet not less than four times a year. The AQSE Rules Compliance Committee will ensure that procedures, resources and controls are in place to ensure that the Company's compliance with the AQSE Rules is operating effectively at all times and that the executive Directors are communicating effectively with the Company's AQSE Corporate Adviser regarding the Company's ongoing compliance with the AQSE Rules and in relation to all announcements and notifications and potential transactions.